MARKET

CRMD

CRMD

Cormedix
NASDAQ
3.540
0.000
0.00%
After Hours: 3.540 0 0.00% 16:01 02/29 EST
OPEN
3.600
PREV CLOSE
3.540
HIGH
3.640
LOW
3.540
VOLUME
270.78K
TURNOVER
0
52 WEEK HIGH
6.09
52 WEEK LOW
2.570
MARKET CAP
194.03M
P/E (TTM)
-4.1331
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CRMD last week (0219-0223)?
Weekly Report · 3d ago
Weekly Report: what happened at CRMD last week (0212-0216)?
Weekly Report · 02/19 11:01
Weekly Report: what happened at CRMD last week (0205-0209)?
Weekly Report · 02/12 10:52
Weekly Report: what happened at CRMD last week (0129-0202)?
Weekly Report · 02/05 10:59
CorMedix Announces DefenCath Launch and CMS Benefit Approval
TipRanks · 01/31 10:13
Cormedix: Current report
Press release · 01/31 00:01
Buy Rating Affirmed on Cormedix Following DefenCath Reimbursement Approval and Strong Launch Outlook
TipRanks · 01/30 20:35
Buy Rating Affirmed: Cormedix’s DefenCath Poised for Success with Positive Reimbursement Outlook and Strategic Launch Plan
TipRanks · 01/30 17:45
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.